A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Amgen
Amgen
Eli Lilly and Company
AbbVie
Hoffmann-La Roche
Hoffmann-La Roche
EMD Serono
Norwegian University of Science and Technology
AbbVie
Qilu Pharmaceutical Co., Ltd.
Abramson Cancer Center at Penn Medicine
Gustave Roussy, Cancer Campus, Grand Paris
University of Sydney
Spanish Lung Cancer Group
Kalbe International Pte. Ltd
Helsinn Healthcare SA
Helsinn Healthcare SA
Sumitomo Pharma America, Inc.
Amgen
Centus Biotherapeutics Limited
AbbVie
University of Turin, Italy
Clovis Oncology, Inc.
Shanghai University of Traditional Chinese Medicine
Shanghai University of Traditional Chinese Medicine
AbbVie
Ospedale Santa Croce-Carle Cuneo
Daiichi Sankyo
Shanghai Gebaide Biotechnology Co., Ltd.
Amgen
Mario Negri Institute for Pharmacological Research
Bayer
GlaxoSmithKline
INSYS Therapeutics Inc
Ontario Clinical Oncology Group (OCOG)
AstraZeneca
Hellenic Oncology Research Group
Ontario Clinical Oncology Group (OCOG)
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hellenic Oncology Research Group
Hellenic Oncology Research Group
Amgen
Pharmacyclics LLC.